POINT Biopharma Global Inc. (PNT, $6.81) is expected to report earnings to fall+70% to -26 cents per share on March 24
POINT Biopharma Global Inc. (PNT) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. The company is set to report its earnings on March 24, and analysts are expecting a significant drop in earnings per share. According to analysts' estimates, the company's earnings per share are expected to fall by 70% to -26 cents per share.
This news follows the company's last earnings report on September 30, which showed earnings per share of -86 cents, missing the estimate of -28 cents. This miss in earnings was likely due to the high costs associated with research and development, which is typical for a clinical-stage pharmaceutical company.
Looking at the company's valuation metrics, we can see that the P/B ratio is normal, sitting around the industry mean of 21.747. The P/E ratio of 0.000 is within average values for comparable stocks, averaging 125.520. The projected growth (PEG ratio) of 0.000 is also within normal values, averaging 3.734. However, the company does not pay a dividend, settling around the average of 0.028 among similar stocks. The P/S ratio of 0.000 is also within normal values, averaging 303.071.
Currently, with 607.70K shares outstanding, the company's market capitalization sits at 722.61M.
Despite these metrics, the stock has been in a downward trend, falling for three consecutive days on March 23, 2023. This trend is viewed as bearish, and investors should keep an eye on this stock for future declines. According to data from situations where PNT declined for three days, in 116 of 145 cases, the price declined further within the following month. Therefore, the odds of a continued downward trend are 80%.
We invite you to check out our premium products -- they’ll help you be best prepared to take on the market. One of the premium products that might be helpful for a new trader is the AI Pattern Search Engine. For a continuing trader, AI Real Time Patterns and our Screener, are a great way to pinpoint exactly what you’re looking for and to monitor the securities for an extended period of time.
Contributor
Advertisement
General Information
Industry Biotechnology
Advertisement